Cisplatin
Cisplatin is a highly effective and broad-spectrum chemotherapeutic agent [1].
Cisplatin is an anticancer agent with some side effects. It is believed to induce apoptosis through several mechanisms. The traditional mechanism is that cisplatin enters the cell, interacts with the DNA guanine bases and forms the inter- or intra-strand chain cross-linking, then prevents the replication of DNA. This formation can also induce apoptosis by activating p53. Cisplatin was also found to cause ROS generation and increase lipid peroxidation, which leads cells to the apoptotic pathway. In addition, cisplatin induces apoptosis with the caspase-dependent pathway. In cochlear cells, cisplatin treatment results in the increase of caspases-3 and -9 and causes the cochlear damage side effect [1].
References:
[1] Casares C, Ramírez-Camacho R, Trinidad A, et al. Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal models. European Archives of Oto-Rhino-Laryngology, 2012, 269(12): 2455-2459.
- 1. Xin Qi, Jiang Zhou, et al. "KLF7-Regulated ITGA2 as a Therapeutic Target for Inhibiting Oral Cancer Stem Cells." bioRxiv 5 November 2024
- 2. Yadan Du, Yawen Chen, et al. "Zinc finger protein 263 promotes colorectal cancer cell progression by activating STAT3 and enhancing chemoradiotherapy resistance." Sci Rep. 2024 Sep 18;14(1):21827. PMID: 39294234
- 3. Ben Ewen-Campen, Norbert Perrimon, et al. "Wnt signaling modulates the response to DNA damage in the Drosophila wing imaginal disc by regulating the EGFR pathway." PLoS Biol. 2024 Jul 24;22(7):e3002547 PMID: 39047051
- 4. Xi Chen, Yuanliang Yan, et al. "Tabersonine enhances cisplatin sensitivity by modulating Aurora kinase A and suppressing epithelial–mesenchymal transition in triple-negative breast cancer." Pharm Biol. 2024 Dec;62(1):394-403. PMID: 38739003
- 5. Ying Cai, Yun Li, et al. "TCEB3 initiates ovarian cancer apoptosis by mediating ubiquitination and degradation of MCL-1." FASEB J. 2024 Apr 30;38(8):e23625. PMID: 38661028
- 6. Yinan Jiang, Shuting Huang, et al. "Targeting the Cdc2‐like kinase 2 for overcoming platinum resistance in ovarian cancer." MedComm (2020). 2024 Apr 13;5(4):e537. PMID: 38617434
- 7. Jiangping Yang, Liujie Qin, et al. "Network pharmacology, molecular docking and experimental study of CEP in nasopharyngeal carcinoma." J Ethnopharmacol. 2024 Apr 6:323:117667. PMID: 38159821
- 8. Xianglai Jiang, Yongfeng Wang, et al. "Cisplatin promotes pyroptosis of gastric cancer cells by activating GSDME." medRxiv. September 08, 2023.
- 9. huidong Liu, Xiao Zhang, et al. "MiR-21-5p delivered by exosomes of placental mesenchymal stem cells targets the PTEN/AKT/mTOR axis to inhibit ovarian granulosa cell apoptosis." Research Square. 04 Aug, 2023.
- 10. Teng Xu, Yuemei Yang, et al. "TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling." J Exp Clin Cancer Res. 2023 Aug 1;42(1):190. PMID: 37525222
- 11. Min Chen, Siyang Zuo, et al. "Pharmacological inhibition of SMYD2 protects against cisplatin-induced renal fibrosis and inflammation." J Pharmacol Sci. 2023 Sep;153(1):38-45. PMID: 37524453
- 12. Ruikai Wang, Amin Li, et al. "BEZ235 reduction of cisplatin resistance on wild-type EGFR non-small cell lung cancer cells." J Chemother. 2022 Mar 3;1-9. PMID: 35238281
- 13. En-Ming Tian, Ming-Cheng Yu, et al. "RORγt agonist synergizes with CTLA-4 antibody to inhibit tumor growth through inhibition of Treg cells via TGF-β signaling in cancer." Pharmacol Res. 2021 Oct;172:105793. PMID: 34339836
- 14. JING CHU, JINGHAI GAO, et al. "Mechanism of hydrogen on cervical cancer suppression revealed by high?throughput RNA sequencing." Oncol Rep. 2021 Jul;46(1):141. PMID: 34080660
- 15. Gang Wang, Qikai Sun, et al. "The stabilization of yes-associated protein by TGFβ-activated kinase 1 regulates the self-renewal and oncogenesis of gastric cancer stem cells." J Cell Mol Med. 2021 Jul;25(14):6584-6601. PMID: 34075691
- 16. Cheng-Wei Chou, Ri-Yao Yang, et al. "The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer." Am J Cancer Res 2020 Aug 1;10(8):2621-2634. PMID: 32905506
- 17. Guo J, Xu G, et al. "Low Expression of Smurf1 Enhances the Chemosensitivity of Human Colorectal Cancer to Gemcitabine and Cisplatin in Patient-Derived Xenograft Models." Transl Oncol. 2020;13(9):100804. PMID: 32512228
- 18. Li A, Cao W, et al. "Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells." J Cancer Res Clin Oncol. 2020;146(7):1737-1749. PMID: 32342201
- 19. Mikhail Chesnokov, Imran Khan, et al. "The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma." bioRxiv. 2019 September 16.
- 20. Chen Z, Tian D, et al. "Apigenin Combined With Gefitinib Blocks Autophagy Flux and Induces Apoptotic Cell Death Through Inhibition of HIF-1α, c-Myc, p-EGFR, and Glucose Metabolism in EGFR L858R+T790M-Mutated H1975 Cells." Front Pharmacol. 2019 Mar 22;10:260. PMID: 30967777
- 21. Zhang B, Cui B, et al. "ATR activated by EB virus facilitates chemotherapy resistance to cisplatin or 5-fluorouracil in human nasopharyngeal carcinoma." Cancer Manag Res. 2019 Jan 9;11:573-585. PMID: 30666155
- 22. Wu Q, Wei X, et al. "Bionic 3D spheroids biosensor chips for high-throughput and dynamic drug screening." Biomed Microdevices. 2018 Sep 15;20(4):82. PMID: 30220069
- 23. Yeo SK, Paul R, et al. "Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer." Autophagy. 2018;14(7):1214-1225. PMID: 29938573
- 24. Sharma K, Vu TT, et al. "p53-independent Noxa induction by cisplatin is regulated by ATF3/ATF4 in head and neck squamous cell carcinoma cells." Mol Oncol. 2018 Jan 19. PMID: 29352505
- 25. Lochmann TL, Floros KV, et al. "Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression." Clin Cancer Res. 2018 Jan 15;24(2):360-369. PMID: 29118061
| Physical Appearance | A solid |
| Storage | Store at RTIt is recommended to store in the form of powder in the dark, the solution is very unstable (Prepare Solution fresh and use at room temperature), DMF is recommended, DMSO can inactivate Cisplatin's activity. |
| M.Wt | 300.05 |
| Cas No. | 15663-27-1 |
| Formula | Cl2H6N2Pt |
| Synonyms | CDDP |
| Solubility | insoluble in EtOH; insoluble in H2O; ≥12.5 mg/mL in DMF |
| Chemical Name | azane;dichloroplatinum(2+) |
| SDF | Download SDF |
| Canonical SMILES | N.N.Cl[Pt+2]Cl |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
|
Cell lines |
L1210/0 cells |
|
Preparation method |
The solubility of this compound in DMF is >12.5 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. |
|
Reaction Conditions |
0, 0.5, 1, 2, 4 and 8 μg/mL; 2 hrs |
|
Applications |
At low concentrations, Cisplatin induced minimal cell death. At higher concentrations, cell death was obvious with only 4% viability. By 10 days after incubation, these few survivors begun to grow and became the predominant cells in the population. |
| Animal experiment [2]: | |
|
Animal models |
Nude mice bearing human ovarian cancer OVCAR-3 cell xenografts |
|
Dosage form |
5 mg/kg, i.v.; at day 0 and day 7 |
|
Applications |
Cisplatin (5 mg/kg) given at the day 0 and 7 induced a tumor growth inhibition (GI) (85.1%) of the OVCAR-3 cell xenografts. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res. 1988 Aug 15;48(16):4484-8. [2]. Molthoff CF, Pinedo HM, Schlüper HM, Rutgers DH, Boven E. Comparison of 131I-labelled anti-episialin 139H2 with cisplatin, cyclophosphamide or external-beam radiation for anti-tumor efficacy in human ovarian cancer xenografts. Int J Cancer. 1992 Apr 22;51(1):108-15. |
|
| Description | Cisplatin is a highly effective and broad-spectrum chemotherapeutic agent. | |||||
| Targets | ||||||
| IC50 | ||||||
Quality Control & MSDS
- View current batch:
Chemical structure
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
